2022年度甲状腺癌研究及诊疗新进展

doi:10.19401/j.cnki.1007-3639.2023.05.001

中国癌症杂志 ›› 2023, Vol. 33 ›› Issue (5): 423-430.doi: 10.19401/j.cnki.1007-3639.2023.05.001

2022年度甲状腺癌研究及诊疗新进展

渠宁(), 王钰婷, 马奔, 王宇()

复旦大学附属肿瘤医院头颈外科，复旦大学上海医学院肿瘤学系，上海 200032

收稿日期:2023-03-20 修回日期:2023-05-08 出版日期:2023-05-30 发布日期:2023-06-16
通信作者: 王宇（ORCID: 003-2622-294X），博士研究生导师、主任医师，复旦大学附属肿瘤医院头颈外科主任。
作者简介:渠宁（ORCID: 0000-0001-5670-4451），博士，副主任医师。
王宇，主任医师，博士研究生导师，复旦大学附属肿瘤医院头颈外科主任。擅长头颈部常见良恶性肿瘤的手术治疗及综合治疗。致力于甲状腺及头颈部肿瘤腔镜和机器人手术，保留功能的喉、喉咽手术，口腔癌、局部晚期甲状腺癌等头颈部肿瘤术后缺损的修复与重建，晚期甲状腺癌、头颈部恶性肿瘤的综合治疗及探索性治疗。作为主持及主要参与者参加30余项国家级、省级、市局级及国际多中心基础及临床试验。主持多项甲状腺癌、头颈部肿瘤临床试验及适宜技术推广项目。作为第一作者及通信作者在国内核心期刊及SCI收录期刊Head and Neck、Thyroid、Cell Discovery上发表论文60余篇。担任多个国内核心期刊及SCI收录期刊的编委及审稿专家。担任国家癌症中心国家肿瘤质控中心甲状腺癌质控专家委员会委员、中国抗癌协会甲状腺肿瘤专业委员会副主任委员、中国医药教育协会头颈肿瘤专业委员会副主任委员、中国医疗保健国际交流促进会普通外科学分会副主任委员、中国抗癌协会头颈肿瘤专业委员会常委、上海市抗癌协会头颈肿瘤专业委员会候任主任委员。曾获多项全国性竞赛奖项。
基金资助:
国家自然科学基金面上项目(82072951);上海市科学技术委员会医学创新专项(22Y21900100);国家自然科学基金青年项目(82203052)

Advances in basic research, clinical diagnosis and treatment of thyroid cancer in 2022

QU Ning(), WANG Yuting, MA Ben, WANG Yu()

Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Received:2023-03-20 Revised:2023-05-08 Published:2023-05-30 Online:2023-06-16
Contact: WANG Yu

摘要/Abstract

摘要：

甲状腺癌是近年来发病率显著升高的内分泌系统恶性肿瘤，治疗以外科治疗为主，术后根据情况辅以内分泌治疗、放射性核素治疗，某些情况下需辅以放疗、靶向治疗。然而甲状腺癌的死亡率亦有升高趋势，晚期或低分化/去分化患者的预后差且生存时间短。基础和临床研究的推进，使得甲状腺癌的个体化治疗取得了新进展。现对2022年度甲状腺癌领域的研究进展进行综述。

关键词: 甲状腺癌, 流行病学, 基础研究, 临床研究, 进展

Abstract:

Thyroid cancer is a common malignancy of the endocrine system with a significantly increased incidence in recent years. Surgical treatment is the primary treatment, followed by endocrine therapy and radionuclide therapy according to the clinical evaluations, and in some cases, radiotherapy and targeted therapy are needed. However, the mortality of thyroid cancer also tends to increase, especially in advanced or low/dedifferentiated patients with poor prognosis and short survival time. With the advancement of basic and clinical research, new progress has been made in individualized treatment of thyroid cancer. This article reviewed the research progress of thyroid cancer in 2022.

Key words: Thyroid cancer, Epidemiology, Basic research, Clinical research, Progress

中图分类号:

R736.1

渠宁, 王钰婷, 马奔, 王宇. 2022年度甲状腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2023, 33(5): 423-430.

QU Ning, WANG Yuting, MA Ben, WANG Yu. Advances in basic research, clinical diagnosis and treatment of thyroid cancer in 2022[J]. China Oncology, 2023, 33(5): 423-430.

参考文献 40

[1]	ZHENG R, ZHANG S, ZENG H, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Center, 2022, 2(1):1-9 doi: 10.1016/j.jncc.2022.02.002
[2]	ZHOU M G, WANG H D, ZENG X Y, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. doi: S0140-6736(19)30427-1 pmid: 31248666
[3]	张新洲, 刘劲松, 许娴, 等. 2005—2016年中国甲状腺癌发病和死亡趋势分析[J]. 中华肿瘤防治杂志, 2022, 29(24): 1725-1733.
	ZHANG X Z, LIU J S, XU X, et al. Trends of thyroid cancer incidence and mortality in China from 2005 to 2016[J]. Chin J Cancer Prev Treat, 2022, 29(24): 1725-1733.
[4]	CHEN W Q, ZHENG R S, ZUO T T, et al. National cancer incidence and mortality in China, 2012[J]. Chin J Cancer Res, 2016, 28(1): 1-11.
[5]	HONGMEI, ZENG, PHD, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567.
[6]	VACCARELLA S, LORTET-TIEULENT J, COLOMBET M, et al. Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study[J]. Lancet Diabetes Endocrinol, 2021, 9(3): 144-152. doi: 10.1016/S2213-8587(20)30401-0
[7]	黄志刚, 陈晓红. 分化型甲状腺癌个体化分层治疗的策略和意义[J]. 中华耳鼻咽喉头颈外科杂志, 2017, 52 (6): 405-409
	HUANG Z G, CHEN X H. The strategy and significance of individualized stratified therapy for differentiated thyroid carcinoma[J]. Chin J Otorhinolaryngol Head Neck Surg, 2017, 52(6): 405-409.
[8]	ROMEI C, CIAMPI R, ELISEI R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma[J]. Nat Rev Endocrinol, 2016, 12(4): 192-202. doi: 10.1038/nrendo.2016.11 pmid: 26868437
[9]	贺青卿, 于芳, 范子义, 等. 单中心2 038例甲状腺癌20年随访及危险因素分析[J]. 中华内分泌外科杂志, 2022, 16(1): 18-22.
	HE Q Q, YU F, FAN Z Y, et al. Risk factor analysis of 20-year follow-up of 2 038 cases of thyroid cancer: a single center study[J]. Chin J Endocr Surg, 2022, 16(1): 18-22.
[10]	LI X C, ZHANG S, ZHANG Q, et al. Diagnosis of thyroid cancer using deep convolutional neural network models applied to sonographic images: a retrospective, multicohort, diagnostic study[J]. Lancet Oncol, 2019, 20(2): 193-201. doi: S1470-2045(18)30762-9 pmid: 30583848
[11]	FRANCO A T, RICARTE-FILHO J C, ISAZA A, et al. Fusion oncogenes are associated with increased metastatic capacity and persistent disease in pediatric thyroid cancers[J]. J Clin Oncol, 2022, 40(10): 1081-1090. doi: 10.1200/JCO.21.01861 pmid: 35015563
[12]	DOOLITTLE W K L, ZHAO L, CHENG S Y. Blocking CDK7-mediated NOTCH1-cMYC signaling attenuates cancer stem cell activity in anaplastic thyroid cancer[J]. Thyroid, 2022, 32(8): 937-948. doi: 10.1089/thy.2022.0087 pmid: 35822558
[13]	ZHANG P T, GUAN H X, YUAN S K, et al. Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors[J]. Nat Commun, 2022, 13(1): 1588. doi: 10.1038/s41467-022-29000-5
[14]	孙海燕, 弓磊, 于振涛, 等. 髓源性抑制细胞联合免疫检查点抑制剂抗肿瘤治疗的研究进展[J]. 肿瘤防治研究, 2020, 47(9)716-721
	SUN H Y, GONG L, YU Z T, et al. Advances in anti-tumor therapy of myeloid-derived suppressor cells combined with immunological checkpoint inhibitors[J]. Cancer Res Prev Treat, 2020, 47(9)716-721
[15]	RABOLD K, ZOODSMA M, GRONDMAN I, et al. Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma[J]. Nat Commun, 2022, 13(1): 6149. doi: 10.1038/s41467-022-33907-4 pmid: 36257966
[16]	YIP L, SOSA J A. Molecular-directed treatment of differentiated thyroid cancer: advances in diagnosis and treatment[J]. JAMA Surg, 2016, 151(7): 663-670. doi: 10.1001/jamasurg.2016.0825 pmid: 27223483
[17]	PENG S, LIU Y H, LV W M, et al. Deep learning-based artificial intelligence model to assist thyroid nodule diagnosis and management: a multicentre diagnostic study[J]. Lancet Digit Health, 2021, 3(4): e250-e259.
[18]	MONTERO-CONDE C, LEANDRO-GARCÍA L J, et al.MARTÍNEZ-MONTES Á M, Comprehensive molecular analysis of immortalization hallmarks in thyroid cancer reveals new prognostic markers[J]. Clin Transl Med, 2022, 12(8): e1001.
[19]	SUN Y T, SELVARAJAN S, ZANG Z L, et al. Artificial intelligence defines protein-based classification of thyroid nodules[J]. Cell Discov, 2022, 8(1): 85. doi: 10.1038/s41421-022-00442-x pmid: 36068205
[20]	SHI X, SUN Y, SHEN C, et al. Integrated proteogenomic characterization of medullary thyroid carcinoma[J]. Cell Discov, 2022, 8(1): 120. doi: 10.1038/s41421-022-00479-y pmid: 36344509
[21]	National Cancer Center, Thyroid Cancer Expert Committee of National Cancer Quality Control Center. Quality control index for standardized diagnosis and treatment of thyroid cancer in China (2022 edition)[J]. Chin J Oncol, 2022, 44(9): 902-907.
[22]	FILETTI S, DURANTE C, HARTL D, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2019, 30(12): 1856-1883. doi: S0923-7534(20)32555-2 pmid: 31987292
[23]	ZHANG Z Y, SUN B T, OUYANG H, et al. Endoscopic lateral neck dissection: a new frontier in endoscopic thyroid surgery[J]. Front Endocrinol (Lausanne), 2021, 12: 796984. doi: 10.3389/fendo.2021.796984
[24]	中国抗癌协会. 中国肿瘤整合诊治指南(CACA)甲状腺癌2022版[M]. 天津科学技术出版社, 2022.
	China Anti-Cancer Association. China Cancer Integrated Diagnosis and Treatment Guidelines (CACA) for thyroid cancer 2022 edition[M]. Tianjin Science and Technology Press, 2022.
[25]	中华人民共和国国家卫生健康委员会医政医管局. 甲状腺癌诊疗指南(2022年版)[J]. 中国实用外科杂志, 2022, 42(12): 1343-1357, 1363.
	National Health Commission of the People’s Republic of China Medical Administration and Hospital Administration. Guidelines for the diagnosis and treatment of thyroid carcinoma[J]. Chin J Pract Surg, 2022, 42(12): 1343-1357, 1363.
[26]	纪玲霞, 周爱琴, 周雪梅. 调强放疗治疗甲状腺癌术后残留和复发的临床效果研究[J]. 实用癌症杂志, 2022, 37(5): 858-860
	JI L X, ZHOU A Q, ZHOU X M. Clinical study on the effect of intensive modulation radiotherapy in the treatment of residue and recurrence after thyroid cancer[J]. Pract J Cancer, 2022, 37(5): 858-860
[27]	KWON J, KIM B H, JUNG H W, et al. The prognostic impacts of postoperative radiotherapy in the patients with resected anaplastic thyroid carcinoma: a systematic review and meta-analysis[J]. Eur J Cancer, 2016, 59: 34-45. doi: S0959-8049(16)00130-1 pmid: 27014798
[28]	ORLANDI F, CARACI P, BERRUTI A, et al. Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer[J]. Ann Oncol, 1994, 5(8): 763-765. pmid: 7826911
[29]	SCHLUMBERGER M, LEBOULLEUX S. Current practice in patients with differentiated thyroid cancer[J]. Nat Rev Endocrinol, 2021, 17(3): 176-188. doi: 10.1038/s41574-020-00448-z pmid: 33339988
[30]	HO A L, DEDECJUS M, WIRTH L J, et al. Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer: a phase Ⅲ, randomized, placebo-controlled trial (ASTRA)[J]. J Clin Oncol, 2022, 40(17): 1870-1878. doi: 10.1200/JCO.21.00714
[31]	CAO J J, ZHU X L, SUN Y R, et al. The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer[J]. Eur J Nucl Med Mol Imaging, 2022, 49(10): 3470-3481. doi: 10.1007/s00259-022-05820-x
[32]	NABHAN F, DEDHIA P H, RINGEL M D. Thyroid cancer, recent advances in diagnosis and therapy[J]. Int J Cancer, 2021, 149(5): 984-992. doi: 10.1002/ijc.33690 pmid: 34013533
[33]	National Comprehensive Cancer Network. NCCN clinical practice guidelines in thyroid cancer (2022 version Ⅰ)[DB/OL]. [2023-04-28]. http://www.nccn.org.
[34]	SUBBIAH V, KREITMAN R J, WAINBERG Z A, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase Ⅱ ROAR basket study[J]. Ann Oncol, 2022, 33(4): 406-415. doi: 10.1016/j.annonc.2021.12.014
[35]	HUANG N S, WEI W J, XIANG J, et al. The efficacy and safety of anlotinib in neoadjuvant treatment of locally advanced thyroid cancer: a single-arm phase Ⅱ clinical trial[J]. Thyroid, 2021, 31(12): 1808-1813. doi: 10.1089/thy.2021.0307
[36]	SARONNI D, GAUDENZI G, DICITORE A, et al. Preclinical evaluation of novel tyrosine-kinase inhibitors in medullary thyroid cancer[J]. Cancers (Basel), 2022, 14(18): 4442. doi: 10.3390/cancers14184442
[37]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021[J]. 肿瘤预防与治疗, 2021, 34(12): 1164-1201.
	Working Committee of the Guidelines of the Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology (CSCO) differentiated thyroid cancer[J]. J Cancer Control Treat, 2021, 34(12): 1164-1201.
[38]	SUBBIAH V, HU M I, WIRTH L J, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study[J]. Lancet Diabetes Endocrinol, 2021, 9(8): 491-501. doi: 10.1016/S2213-8587(21)00120-0
[39]	RAMAN R, VILLEFRANC J A, ULLMANN T M, et al. Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer[J]. J Exp Med, 2022, 219(6): e20210390.
[40]	LEE Y A, LEE H, IM S W, et al. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake[J]. J Clin Invest, 2021, 131(18): e144847.
	WAGUESPACK S G, DRILON A, LIN J J, et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma[J]. Eur J Endocrinol, 2022, 186(6): 631-643. doi: 10.1530/EJE-21-1259

2022年度甲状腺癌研究及诊疗新进展

Advances in basic research, clinical diagnosis and treatment of thyroid cancer in 2022

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 40

相关文章 15

编辑推荐

Metrics

本文评价

[1]	蒋金玲, 周尘飞, 王超, 赵丽琴, 吴珺玮, 张俊. 2022年度胃癌研究和诊疗新进展[J]. 中国癌症杂志, 2023, 33(4): 303-314.
[2]	赵海潮, 高强. 2022年度肝癌研究及诊疗新进展[J]. 中国癌症杂志, 2023, 33(4): 315-326.
[3]	田熙, 徐文浩, 朱殊璇, 艾合太木江·安外尔, 宿佳琦, 叶世琪, 瞿元元, 施国海, 张海梁, 叶定伟. 2022年度肾细胞癌基础研究及临床诊疗新进展[J]. 中国癌症杂志, 2023, 33(3): 191-200.
[4]	郑盛锋, 朱一平, 叶定伟. 2022年度膀胱癌基础研究及临床诊疗新进展[J]. 中国癌症杂志, 2023, 33(3): 201-209.
[5]	潘剑, 朱耀, 戴波, 叶定伟. 2022年度前列腺癌基础研究及临床诊疗新进展[J]. 中国癌症杂志, 2023, 33(3): 210-217.
[6]	曾铖, 张剑. 2022年度ADC在胰腺癌领域的研究新进展及展望[J]. 中国癌症杂志, 2023, 33(3): 235-240.
[7]	张会强, 江泽飞. 2022年改变晚期乳腺癌临床实践的重要研究[J]. 中国癌症杂志, 2023, 33(2): 110-116.
[8]	王子彧, 肖毅, 江一舟, 邵志敏. 2022年乳腺癌基础与转化研究进展[J]. 中国癌症杂志, 2023, 33(2): 95-102.
[9]	王旭, 程合, 刘辰, 虞先濬. 2022年度胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2023, 33(1): 1-13.
[10]	郭勤浩, 余敏, 吴小华. 2022年度妇科肿瘤诊治进展[J]. 中国癌症杂志, 2023, 33(1): 14-24.
[11]	吴建辉, 储香玲, 王李强, 林心情, 谢晓鸿, 谢梦青, 赵静, 邓海怡, 杨伊霖, 邱桂焕, 周茂林, 孙霓, 李茹, 陈萤, 邓佳茜, 曾晨, 潘柏林, 秦茵茵, 刘明, 苏春霞, 周承志. 中国肺癌患者真实世界免疫检查点抑制剂相关性肺炎的流行病学分析[J]. 中国癌症杂志, 2022, 32(6): 469-477.
[12]	曲以平, 侯鹏. 转移性儿童甲状腺癌的遗传学特征和预后[J]. 中国癌症杂志, 2022, 32(5): 373-379.
[13]	孙迪, 孙郁青, 张鑫, 黄丽莎, 林岩松. 局部晚期或转移性儿童及青少年分化型甲状腺癌的基因特征与临床特征及¹³¹I疗效的关系[J]. 中国癌症杂志, 2022, 32(5): 380-387.
[14]	邓姝婷, 冯源, 钱凯, 郭凯, 王卓颖. 基因突变特征与儿童及青少年分化型甲状腺癌远处转移相关性的meta分析[J]. 中国癌症杂志, 2022, 32(5): 388-396.
[15]	刘佳, 李广涵, 高璐滢, 张紫杰, 王莹, 熊颖, 张波. 儿童及青少年甲状腺结节分级诊断模型的建立与验证[J]. 中国癌症杂志, 2022, 32(5): 397-403.